secwatch.observer — SEC 8-K summary
======================================

Issuer:     Context Therapeutics Inc. (CNTX)
CIK:        0001842952
Form:       8-K
Filed at:   2026-11-10T21:23:34+00:00
Accession:  0001628280-26-072768
Event type: earnings
Sentiment:  positive
Materiality: 0.72
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Context Therapeutics Q3 net loss $7.6M; CTIM-76 shows 22% ORR in PROC at weekly doses
--------------------------------------------------------------------------------

- Q3 2026 net loss $7.6M vs $9.7M in Q3 2025; R&D $5.7M vs $8.7M, G&A $2.2M vs $1.9M.
- Cash and equivalents $34.4M at Sept 30, 2026, down from $66.0M at Dec 31, 2025; runway expected into early Q4 2027.
- CTIM-76 in 9 efficacy-evaluable PROC patients at 140–280 µg weekly: 22% confirmed ORR, 56% DCR, median PFS 5.6 months.
- Safety: CRS in 5 of 27 patients (18.5%), all Grade 1/2; Grade ≥3 TEAEs in 81.5%, with dose-related Grade ≥3 liver enzyme elevations.
- DLT period at 280 µg every three weeks complete; escalation to 420 µg Q3W begun; Phase 1b initiation expected Q1 2027, initial Q3W efficacy data Q2 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842952/000162828026072768/0001628280-26-072768-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842952/000162828026072768/cntx-20261110.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-072768

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer